Thermo Fisher Scientific Prices Offering of Senior Notes

On September 25, 2019 Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") reported that it has priced an offering of €4.4 billion aggregate principal amount (the "Euro Offering") of euro-denominated notes (collectively, the "Euro Notes") and an offering of $900 million aggregate principal amount (the "USD Offering" and, together with the Euro Offering, the "Offerings") of USD-denominated notes (collectively, the "USD Notes") (Press release, Thermo Fisher Scientific, SEP 25, 2019, View Source [SID1234539771]). The following notes were priced:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

€800 million aggregate principal amount of its 0.125% senior notes due 2025, at the issue price of 99.114% of their principal amount,
€800 million aggregate principal amount of its 0.500% senior notes due 2028, at the issue price of 99.060% of their principal amount,
€900 million aggregate principal amount of its 0.875% senior notes due 2031, at the issue price of 99.243% of their principal amount,
€900 million aggregate principal amount of its 1.500% senior notes due 2039, at the issue price of 99.743% of their principal amount,
€1,000 million aggregate principal amount of its 1.875% senior notes due 2049, at the issue price of 98.465% of their principal amount, and
$900 million aggregate principal amount of its 2.600% senior notes due 2029, at the issue price of 99.861% of their principal amount.
The Euro Offering is expected to close on or about September 30, 2019, and the USD Offering is expected to close on or about October 8, 2019, subject to customary closing conditions. The Euro Notes will pay interest on an annual basis. The USD Notes will pay interest on a semi-annual basis. Closing of the Euro Offering is not contingent upon the completion of the USD Offering, and closing of the USD Offering is not contingent upon the completion of the Euro Offering.

Thermo Fisher intends to use the net proceeds of the Offerings (together with cash on hand) to repay commercial paper issued to fund the redemption on September 27, 2019, of $300 million aggregate principal amount of its 4.70% Senior Notes due 2020 and $800 million aggregate principal amount of its 3.15% Senior Notes due 2023, and to fund the redemption of approximately $4.5 billion aggregate principal amount of outstanding senior notes issued by Thermo Fisher or its subsidiaries, including all of the outstanding 6.00% Senior Notes due 2020 and 5.00% Senior Notes due 2021 issued by its subsidiary Life Technologies Corporation, of which notice is expected to be provided to holders tomorrow.

The joint book-running managers for the Euro Offering are Goldman Sachs & Co. LLC, Merrill Lynch International, Citigroup Global Markets Limited and J.P. Morgan Securities plc. The joint book-running managers for the USD Offering are Goldman Sachs & Co. LLC, BofA Securities, Inc., Credit Suisse Securities (USA) LLC and HSBC Securities (USA) Inc.

The Offerings are being made pursuant to an effective registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission (the "SEC"). Prospective investors should read the prospectus forming a part of that registration statement and the separate prospectus supplements related to the Offerings and the other documents that Thermo Fisher has filed with the SEC for more complete information about Thermo Fisher and the Offerings. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Thermo Fisher, the underwriters or any dealer participating in the Euro Offering will arrange to send you the related prospectus if you request it by calling Merrill Lynch International toll-free at 1-800-294-1322; Goldman Sachs & Co. LLC toll-free at 1-866-471-2526; Citigroup Global Markets Limited toll-free at 1-800-831-9146; or J.P. Morgan Securities plc collect on +44-207-134-2468; and Thermo Fisher, the underwriters or any dealer participating in the USD Offering will arrange to send you the related prospectus if you request it by calling BofA Securities, Inc. toll-free at 1-800-294-1322; Goldman Sachs & Co. LLC toll-free at 1-866-471-2526; Credit Suisse Securities (USA) LLC at 1-800-221-1037; or HSBC Securities (USA) Inc. toll-free at 1-866-811-8049.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Viking Therapeutics to Present at 2019 Cantor Global Healthcare Conference

On September 25, 2019 Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, reported that the company will deliver a corporate presentation at the 2019 Cantor Global Healthcare Conference, being held October 2-4, 2019 in New York, NY (Press release, Viking Global Investors, SEP 25, 2019, View Source [SID1234539790]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for this presentation are as follows:

2019 Cantor Global Healthcare Conference – webcast available
Time/Date: 4:45 p.m. Eastern on Wednesday, October 2, 2019
Location: InterContinental New York Barclay Hotel
Room: Grand Ballroom 2
To access the live webcast of Viking’s presentation, please visit "Webcasts & Presentations" within the News & Events section of Viking’s Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.

Bio-Path Updates Intellectual Property Portfolio with Addition of Recently
Issued Second Platform Technology Patent

On September 25, 2019 Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, reported that the United States Patent and Trademark Office has issued a patent with claims related to the Company’s proprietary liposomal delivery and antisense technology, DNAbilize, including its use in the treatment of cancers, autoimmune diseases and infectious diseases (Press release, Bio-Path Holdings, SEP 25, 2019, View Source [SID1234539772]). This is the second U.S. patent issued for the Company’s platform technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new patent, United States Patent No. 10,335,428 (based on Application No. 15/657,083), titled "P-Ethoxy Nucleic Acids for Liposomal Formulation," which issued July 2, 2019, provides additional claims for the broad protection previously granted in Patent No. US 9,744,187 (issued August 29, 2017) for application of the DNAbilize technology in the treatment of a variety of cancers, as well as autoimmune and infectious diseases. DNAbilize is a proprietary liposomal nanoparticle delivery and antisense technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion.

Bio-Path’s platform technology patents allow the Company to develop new drug product candidates using its proprietary DNAbilize technology. As new drug product candidates are developed using DNAbilize technology, new patent applications can be filed for the specific drug products incorporating DNAbilize technology.

Applying the DNAbilize technology to a protein target can result in a specific drug product for which a new DNAbilize drug product patent application can be filed. The Company anticipates that the number of DNAbilize drug product candidates will increase significantly in the coming years.

The Company believes its patented platform technology provides a powerful template with the capability to produce a large portfolio of patented drug products. The Company currently has two issued platform technology patents for DNAbilize and five pending patent applications for specific DNAbilize drug product candidates. Each of the issued technology platform patents has a life of twenty years from filing, and any issued patents for specific DNAbilize drug products will also be protected for twenty years from filing.

Consequently, the Company expects its expanding intellectual property estate for DNAbilize to be a source of both exciting breakthroughs in cancer therapy and to be an engine for out-licensing opportunities across a broad spectrum of cancer indications with currently unmet medical needs.

"Our strategy is to leverage the value of our patented DNAbilize technology by focusing on our mission to develop systemic DNAbilize treatments for hard-to-treat diseases. In doing so, we believe we can develop multiple drug products that can enhance shareholder value through partnering or licensing at various stages of drug product development. This will allow Bio-Path to focus on the front-end of the development process, while partnering out development through later stages of clinical development," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

OncoQuest Receives "Notice of Allowance" for Patent Protection of the Administration Schedule of Oregovomab and Chemotherapy for Stage III-IV Ovarian Cancer Patients

On September 25, 2019 OncoQuest Inc., a privately held, cancer immunotherapy company reported that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for patent protection of the schedule of administration of our monoclonal anti-CA-125 antibody, mAb-B43.13, now known as oregovomab, in a specific schedule in combination with carboplatin and paclitaxel in Stage III-IV ovarian cancer patients (Press release, OncoQuest, SEP 25, 2019, View Source [SID1234539791]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A Notice of Allowance signifies that the applicant is entitled to receive patent protection of 20 years under the law. The patent claim lays out a specific schedule of administration of oregovomab in combination with carboplatin and paclitaxel, and as a standalone injection 10 to 14 weeks after the third oregovomab administration. This administration protocol generated a statistically significant Progression Free and Overall Survival advantage over chemotherapy alone in a 97-patient randomized controlled Phase 2 study in newly diagnosed Stage III-IV ovarian cancer patients which was completed in 2017 [NCT01616303].

The Company is currently planning to launch a Phase 3 trial in Q1 2020. The planned Phase 3 study is expected to enroll over 500 patients with newly diagnosed, advanced ovarian cancer globally. The primary endpoint will be to evaluate progression-free survival of patients treated with oregovomab plus a standard-of-care chemotherapy combination, carboplatin and paclitaxel, compared to the chemotherapy alone.

"We are very pleased that this additional patent was allowed as it is a significant addition to our oregovomab patent portfolio, providing extended exclusivity protection, in addition to what we are already expecting from the Biologics Price Competition and Innovation Act (BPCIA)," said Dr. Madiyalakan, CEO of OncoQuest. "This marks an important step in our ongoing efforts to optimize the value of our oregovomab product as we embark on our initiation of the Phase III registration study and towards commercialization of oregovomab."

X4 Pharmaceuticals to Attend Two Upcoming Investor Conferences

On September 25, 2019 X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, reported that the management team is scheduled to conduct one-on-one meetings at the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies, and to present and conduct one-on-one meetings at the 2019 Cantor Global Healthcare Conference (Press release, X4 Pharmaceuticals, SEP 25, 2019, View Source [SID1234539587]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details related to the team’s participation are as follows:

Conference:
Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies

Location:

New York, NY

Date:

September 23rd

Conference:

2019 Cantor Global Healthcare Conference

Location:

New York, NY

Presentation Date & Time:

October 2nd at 4:10 pm EDT